TARGET SITES: Finland, Sweden
NUMBER OF PATIENTS: 78-90
AGE OF PATIENTS: 18-45 years
CRO: SCRO (Scandinavian CRO) based in Uppsala Sweden
TREATMENT: prophylactic neurosteroid Sepranolone
ADMINISTRATION: pre-filled syringes for self-administration
TIMELINE: full patient enrolment reached September 2020, topline results expected Q2 2021